Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Mylan Labs -- Ignore unavailable to you. Want to Upgrade?

To: David Lawrence who wrote (274)	4/6/1998 9:03:00 PM
From: J.K.B.	Read Replies (1) \| Respond to of 384

D.L. I understand what you are saying. But if they decide to pull Mylan from their formulary the patient has no options, not the pharmacy. It will not matter where they get their prescription filled Mylan will not be covered. They will probably follow the same path that PCS has made and give the patient an entirely different medication. An example might be Dyazide for Lasix. or Xanax for Ativan. Their are generics for all of the brand name products listed above. Our pharmacies will carry the product, but we have already seen the price sky-rocket to a point where some customers are asking our pharmacists to call their physician and request a different medication that does have a cheaper generic. This probably will not mean anything to the price of the stock, unless other insurance companies like PCS, PAID, and Medicaid follow suit. FYI: I am high on Mylan. I own options on the stock. But we all need to proceed with caution. If I receive any other letters from providers I will forward them. Good luck. J.K.B.